Chemoprevention of breast cancer

Women's Health

Volumn 8, Issue 6, 2012, Pages 635-646

  Files, Julia A ^a   Stan, Daniela L ^b   Allen, Summer V ^b   Pruthi, Sandhya ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

aromatase inhibitor; breast cancer prevention; breast cancer risk; chemoprevention; Gail Model; high risk women; raloxifene; tamoxifen

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTHRALGIA; ARTHRITIS; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; COMPARATIVE EFFECTIVENESS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FATIGUE; FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; LUNG EMBOLISM; NAUSEA; NIGHT SWEAT; OSTEOPOROSIS; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; FEMALE; HEALTH EDUCATION; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT PREFERENCE; PHYSICIAN-PATIENT RELATIONS; PRIMARY PREVENTION; QUALITY OF LIFE; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 84870438838     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.12.56     Document Type: Review

References (72)

1. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354(3), 270-282 (2006).
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
3. Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 356(16), 1670-1674 (2007). (Pubitemid 46631679)
4. Banks E, Canfell K. Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. Breast Cancer Res. 12(1), 103 (2010).
5. Matloff ET, Shannon KM, Moyer A, Col NF. Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling. J. Cancer Educ. 22(1), 10-14 (2007). (Pubitemid 47110494)
6. Fagerlin A, Dillard AJ, Smith DM et al. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res. Treat. 127(3), 681-688 (2011).
7. Pruthi S, Brandt KR, Degnim AC et al. A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. Mayo Clin. Proc. 82(8), 999-1012 (2007). (Pubitemid 47206376)
8. Nelson HD, Zakher B, Cantor A et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann. Intern. Med. 156(9), 635-648 (2012).
9. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81(24), 1879-1886 (1989). (Pubitemid 20026073)
10. Pankratz VS, Hartmann LC, Degnim AC et al. Assessment of the accuracy of the Gail Model in women with atypical hyperplasia. J. Clin. Oncol. 26(33), 5374-5379 (2008).
11. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P1 Study. J. Natl Cancer Inst. 90(18), 1371-1388 (1998). (Pubitemid 28439961)
12. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P2 trial. JAMA 295(23), 2727-2741 (2006).
13. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P1 study. J. Natl Cancer Inst. 97(22), 1652-1662 (2005). (Pubitemid 41672231)
14. Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann. Intern. Med. 151(10), 703-715, W-2267-35 (2009).
15. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336), 817-824 (2002). (Pubitemid 35257944)
16. Cuzick J, Forbes JF, Sestak I et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96month follow-up of the randomized IBISI trial. J. Natl Cancer Inst. 99(4), 272-282 (2007). (Pubitemid 47073490)
17. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann. Intern. Med. 130(5), 431-439 (1999). (Pubitemid 29111226)
18. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7), 637-645 (1999). (Pubitemid 29384151)
19. Delmas PD, Ensrud KE, Adachi JD et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: fouryear results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87(8), 3609-3617 (2002). (Pubitemid 34879503)
20. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281(23), 2189-2197 (1999). (Pubitemid 29275701)
21. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst. 96(23), 1751-1761 (2004). (Pubitemid 39654569)
22. Vogel VG, Costantino JP, Wickerham DL et al. Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P2 trial: preventing breast cancer. Cancer Prev. Res. (Phila.) 3(6), 696-706 (2010).
23. Breast International Group (BIG) 198 Collaborative Group, Thürlimann B, Keshaviah A et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353(26), 2747-2757 (2005). (Pubitemid 43016814)
24. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324), 2131-2139 (2002). (Pubitemid 34694019)
25. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9), 1802-1810 (2003). (Pubitemid 37310221)
26. Cuzick J. Aromatase inhibitors for breast cancer prevention. J. Clin. Oncol. 23(8), 1636-1643 (2005). (Pubitemid 46211418)
27. Goss PE, Ingle JN, Ales-Martinez JE et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364(25), 2381-2391 (2011).
28. invasive breast cancers with minimal side effects during a median follow-up period of 3 years.
29. Cheung AM, Tile L, Cardew S et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 13(3), 275-284 (2012).
30. Ganz PA, Land SR. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Menopause 15(Suppl. 4), S797-S803 (2008).
31. Land SR, Wickerham DL, Costantino JP et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P2 trial. JAMA 295(23), 2742-2751 (2006).
32. Files JA, Ko MG, Pruthi S. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. Mayo Clin. Proc. 85(6), 560-566; quiz 566 (2010).
33. Ravdin PM. The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev. Res. (Phila.) 3(6), 686-688 (2010).
34. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Clin. Oncol. 17(9), 2659-2669 (1999). (Pubitemid 29415221)
35. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 198. J. Clin. Oncol. 25(5), 486-492 (2007). (Pubitemid 350002953)
36. Gabriel EM, Jatoi I. Breast cancer chemoprevention. Expert Rev. Anticancer Ther. 12(2), 223-228 (2012).
37. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 50(14), 4177-4189 (1990). (Pubitemid 20225648)
38. Obiorah I, Jordan VC. Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas 70(4), 315-321 (2011).
39. Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res. Treat. 134(2), 875-880 (2012).
40. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann. Surg. Oncol. 8(7), 580-585 (2001). (Pubitemid 32735038)
41. Malek K, Fink AK, Thwin SS, Gurwitz J, Ganz PA, Silliman RA. The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer. Med. Care 42(7), 700-706 (2004).
42. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J. Clin. Oncol. 28(18), 3090-3095 (2010).
43. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J. Clin. Oncol. 22(24), 4951-4957 (2004). (Pubitemid 46638620)
44. Waters EA, Weinstein ND, Colditz GA, Emmons K. Explanations for side effect aversion in preventive medical treatment decisions. Health Psychol. 28(2), 201-209 (2009).
45. Jordan VC. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices - point. Cancer Epidemiol. Biomarkers Prev. 16(11), 2207-2209 (2007).
46. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev. Res. (Phila.) 4(9), 1360-1365 (2011).
47. Moy B, Richardson H, Johnston D et al. NCIC CTG MAP.3: enrollment and study drug adherence of ethnic minority women in a breast cancer prevention trial. Breast Cancer Res. Treat. 106(Suppl. 1), S141-S142 (2007) (Abstract only).
48. Land SR, Cronin WM, Wickerham DL et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P1 Breast Cancer Prevention Trial. Cancer Prev. Res. (Phila.) 4(9), 1393-1400 (2011).
49. Hershman DL, Kushi LH, Shao T et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J. Clin. Oncol. 28(27), 4120-4128 (2010).
50. Freedman AN, Yu B, Gail MH et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J. Clin. Oncol. 29(17), 2327-2333 (2011).
51. Gail MH, Costantino JP, Bryant J et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl Cancer Inst. 91(21), 1829-1846 (1999).
52. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J. Natl Cancer Inst. 99(4), 283-290 (2007). (Pubitemid 47073491)
53. Jordan VC, Gosden B. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology 113(2), 463-468 (1983). (Pubitemid 13048932)
54. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45(5), 344-345 (1988).
55. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005).
56. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br. J. Clin. Pharmacol. 41(2), 149-156 (1996). (Pubitemid 26060742)
57. Goetz MP, Schaid DJ, Wickerham DL et al. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin. Cancer Res. 17(21), 6944-6951 (2011).
58. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J. Natl Cancer Inst. 103(17), 1299-1309 (2011).
59. Visvanathan K, Chlebowski RT, Hurley P et al. American Society of Clinical Oncology Clinical Practice Guideline
60. update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol. 27(19), 3235-3258 (2009).
61. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 137(1), 59-69 (2002).
62. Sheridan SL, Harris RP, Woolf SH, Shared decision-making workgroup of the U.S. Preventive Services Task Force. Shared decision making about screening and chemoprevention. a suggested approach from the U.S. Preventive Services Task Force. Am. J. Prev. Med. 26(1), 56-66 (2004). (Pubitemid 38045175)
63. Bevers TB. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J. Natl Compr. Canc. Netw. 5(8), 719-724 (2007). (Pubitemid 47492770)
64. Levine M, Moutquin JM, Walton R et al. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 164(12), 1681-1690 (2001). (Pubitemid 32702087)
65. King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP1) Breast Cancer Prevention Trial. JAMA 286(18), 2251-2256 (2001). (Pubitemid 33063147)
66. Pujol P, Lasset C, Berthet P et al. Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. Fam. Cancer 11(1), 77-84 (2012).
67. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J. Mol. Endocrinol. 48(3), R31-R43 (2012).
68. National Cancer Institute. Surveillance Epidemiology and End Results. Cancer Incidence Rates (2012). http://seer.cancer.gov/statistics/types/ incidence.html
69. National Cancer Institute. Breast Cancer Risk Assessment Tool. www.cancer.gov/bcrisktool
70. IBISII. International Breast Cancer Intervention Study. www.ibis-trials.org
71. National Surgical Adjuvant Breast and Bowel Project: clinical trials overview. Protocol B35. www.nsabp.pitt.edu/B-35.asp
72. Letrozole in treating healthy postmenopausal women at high risk for breast cancer. http://clinicaltrials.gov/show/NCT01077453